Reckitt Benckiser Group’s (RB) “Buy” Rating Reiterated at Deutsche Bank

Deutsche Bank reissued their buy rating on shares of Reckitt Benckiser Group (LON:RB) in a report issued on Friday, Borsen Zeitung reports. They currently have a GBX 8,000 ($104.53) price objective on the stock.

A number of other analysts have also commented on the company. Bryan, Garnier & Co lowered their price objective on GlaxoSmithKline from GBX 1,710 ($22.34) to GBX 1,660 ($21.69) and set a neutral rating for the company in a research report on Thursday, May 2nd. Morgan Stanley reiterated an overweight rating on shares of in a research report on Thursday, June 20th. JPMorgan Chase & Co. set a €33.40 ($38.84) price objective on Siemens Healthineers and gave the stock a neutral rating in a research report on Thursday. HSBC set a $46.00 price objective on Aqua America and gave the stock a buy rating in a research report on Friday, June 28th. Finally, Barclays lifted their price objective on Roper Technologies from $342.00 to $355.00 and gave the stock an equal weight rating in a research report on Tuesday, July 9th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the stock. Reckitt Benckiser Group presently has an average rating of Hold and a consensus target price of GBX 7,244.44 ($94.66).

Reckitt Benckiser Group stock opened at GBX 6,572 ($85.87) on Friday. The firm has a 50-day simple moving average of GBX 6,384.22. The company has a debt-to-equity ratio of 80.49, a current ratio of 0.65 and a quick ratio of 0.47. Reckitt Benckiser Group has a 12-month low of GBX 5,559 ($72.64) and a 12-month high of GBX 7,174 ($93.74). The company has a market capitalization of $46.76 billion and a PE ratio of 21.56.

In other Reckitt Benckiser Group news, insider Adrian Nevil Hennah sold 13,701 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of GBX 6,143 ($80.27), for a total value of £841,652.43 ($1,099,767.97). Also, insider Christopher Sinclair bought 1,076 shares of the business’s stock in a transaction on Thursday, May 23rd. The stock was purchased at an average price of GBX 6,375 ($83.30) per share, for a total transaction of £68,595 ($89,631.52).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.

Further Reading: Compound Interest and Why It Matters When Investing

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with's FREE daily email newsletter.